19:16:37 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Neola Medical

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-23 X-dag ordinarie utdelning NEOLA 0.00 SEK
2024-05-22 Kvartalsrapport 2024-Q1
2024-05-22 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-12-29 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-15 Kvartalsrapport 2023-Q2
2023-05-19 X-dag ordinarie utdelning NEOLA 0.00 SEK
2023-05-17 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-02-14 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-09-27 Extra Bolagsstämma 2022
2022-08-16 Kvartalsrapport 2022-Q2
2022-05-20 X-dag ordinarie utdelning NEOLA 0.00 SEK
2022-05-19 Kvartalsrapport 2022-Q1
2022-05-19 Årsstämma 2022
2022-02-15 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-09-14 Extra Bolagsstämma 2021
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-21 X-dag ordinarie utdelning NEOLA 0.00 SEK
2021-05-20 Kvartalsrapport 2021-Q1
2021-05-20 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neola Medical är verksamt inom medicinteknik. Bolaget är inriktade mot neonatalvården där de utvecklar medicinteknisk utrustning. Exempel på produkter som bolaget tillhandahåller till sjukvården inkluderar teknisk övervakning och uppföljning av lungkapaciteten hos tidigt födda spädbarn. Utöver huvudprodukten erbjuds kringprodukter och engångsartiklar. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget gick tidigare under namnet GPX Medical.
Neola Medical's CEO Announces Key Achievements in the Summer 2024 Investor Letter
2024-06-18 08:50:00

Neola Medical has reached several critical milestones aligned with its business strategy, aimed at market approval by the FDA. A Human Factors Validation Study of the company’s medical device for lung monitoring, Neola®, was successfully concluded with neonatal nurses in the USA, and will lay a foundation for the upcoming market grant application to FDA. Additionally, Neola® obtained a CB certificate according to high International standards, meeting partial regulatory requirements for market approval in the USA.

“These achievements lay a strong foundation for our upcoming FDA application for market approval in the USA. We now advance to the clinical validation phase and intensify planning for the clinical study in the USA on preterm born infants.”, says CEO Hanna Sjöström.

Read more about the latest news in the investor letter summer 2024, attached to this press release and available on the company’s website www.neolamedical.se

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical's CEO Announces Key Achievements in the Summer 2024 Investor Letter
Neola Medical Investor Letter Summer 2024

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden